Last reviewed · How we verify

Cipla — Portfolio Competitive Intelligence Brief

Cipla (CIPLA.NS) pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

CIPLA.NS (NSE) 1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Tasigna NILOTINIB marketed Kinase Inhibitor [EPC] Bcr/Abl fusion protein Oncology 2007-01-01

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ASTRAZENECA LP · 1 shared drug class
  2. AbbVie · 1 shared drug class
  3. AstraZeneca · 1 shared drug class
  4. Bayer · 1 shared drug class
  5. BeiGene · 1 shared drug class
  6. Beigene Usa Inc · 1 shared drug class
  7. Blueprint Medicines · 1 shared drug class
  8. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Cipla:

Cite this brief

Drug Landscape (2026). Cipla — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cipla. Accessed 2026-05-13.

Related